Basic Information
Xenleta
Regulatory Information
EMEA/H/C/005048
July 27, 2020
2
April 29, 2025
Company Information
Ireland
Alexandra House Office 225/227 The Sweepstakes Ballsbridge Dublin 4, D04 C7H2
Nabriva Therapeutics Ireland DAC
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Overview Summary
Xenleta is an antibiotic used in adults to treat community-acquired pneumonia (a lung infection caught outside of hospital) when other antibiotic medicines are not suitable or do not work. Xenleta contains the active substance lefamulin.